Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Overview of attention for article published in Cancer Epidemiology, Biomarkers & Prevention, January 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 1 news outlet
policy: 2 policy sources
twitter: 4 X users

patent: 1 patent
wikipedia: 1 Wikipedia page
guideline: 1 clinical guideline source

Readers on

mendeley: 501 Mendeley
citeulike: 3 CiteULike

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 8,551 followers.

Q387 answer: Triple-negative status https://t.co/NGpovGNkAk https://t.co/iNjLBZSG77 https://t.co/NKp8BGnzcX

RT @radoncreview: TL;DR: BRCA1 behaves like TNBC and has a higher risk of female breast, Ovarian, and cOlon cancer vs BRCA 2. BRCA2 behaves…

TL;DR: BRCA1 behaves like TNBC and has a higher risk of female breast, Ovarian, and cOlon cancer vs BRCA 2. BRCA2 behaves like sporadic (HR+) and is more likely to be associated with male breast cancer. Chen: https://t.co/QpXd0MdKOa CIMBA: https://t.co…

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Co http://t.co/74PWTYlZ

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.